Katy Rezvani, MD, PhD, is a professor at the University of Texas MD Anderson Cancer Center, where she is the Sally Cooper Murray Endowed Chair in Cancer Research, a professor of medicine, the Chief of the Section of Cellular Therapy in the Department of Stem Cell Transplant and Cellular Therapy, Executive Director of the Adoptive Cell Therapy Platform, and Director of Translational Research and Medical Director of the MD Anderson GMP and Cell Therapy Laboratory.

Her lab studies the role of natural-killer (NK) cells in mediating immunity against glioblastoma as well as other solid tumors and seeks to understand the mechanisms of tumor-induced NK cell dysfunction. The goal of her research is to develop strategies for genetically engineering NK cells to enhance their in-vivo anti-tumor activity and persistence.

Her laboratory has extensive experience in multi-parameter flow cytometry, CyTOF, xenogenic NSG mouse models of human cancer, and various molecular biology techniques. She leads the NK immunotherapy program at MD Anderson and translates multiple innovative strategies from bench to bedside, including a first-in-human trial of CAR NK cells in patients with lymphoid malignancies.

She serves as the leader of the Stem Cell Transplantation and Cellular Therapy Program of the MD Anderson Cancer Center Support Grant. She has served as co-PI for the Cancer Medicine Fellowship T32 program at MD Anderson Cancer Center since 2018 and as a CPRIT TRIUMPH faculty mentor since 2019. She has had 19 trainees in her laboratory. Thirteen of her former trainees hold faculty positions at academic institutions. She has also served on the mentoring committees of multiple junior faculty members and the thesis committees of numerous PhD students.